Literature DB >> 30965120

Preparation of in situ hydrogels loaded with azelaic acid nanocrystals and their dermal application performance study.

Ivona Tomić1, Marina Juretić2, Mario Jug3, Ivan Pepić3, Biserka Cetina Čižmek2, Jelena Filipović-Grčić4.   

Abstract

Azelaic acid (AZA) is a dicarboxylic acid that is topically used in the treatment of acne and rosacea since it possesses antibacterial and keratolytic activity. The primary objective of this study was to develop an AZA nanocrystal suspension. It is expected that improved solubility and dissolution rate will result in advanced biopharmaceutical properties, primarily the dermal bioavailability. Furthermore, a topical nanocrystal AZA-loaded hydrogels composed of Pluronic® F127 and hyaluronic acid mixture that are able to deliver AZA into the stratum corneum and deeper skin layers were considered. This study was conducted in order to: 1) determine the effect of non-ionic Polysorbate 60 on the stabilization and particle size of the AZA nanocrystals, as well as the effect of Pluronic® F127, used as an in situ gelation agent, and hyaluronic acid on the viscoelastic properties and the drug release of composed hydrogels, 2) determine the relationship between the rheological properties of the gels and the penetration of AZA into the stratum corneum. The composed hydrogels revealed pseudoplastic flow behaviour. The increase in Pluronic® F127 concentration induced a domination of elastic over viscous behaviour of the gels. The gel containing 15% of Pluronic® F127, 1% of hyaluronic acid and lyophilised 10% nanocrystal AZA suspension was considered to be an optimal formulation, since it possessed the rheological and drug delivery properties desirable for an in situ gelling platform for dermal application.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Azelaic acid; Dermal application; Hydrogels; Nanocrystals

Mesh:

Substances:

Year:  2019        PMID: 30965120     DOI: 10.1016/j.ijpharm.2019.04.016

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Optimization of Experimental Procedure for Determining Azelaic Acid in Cosmetics by Gas Chromatography Derivatized through Ethanol.

Authors:  Jinmei Yang; Qijin Geng; Yaobin Zhou; Yuanfang Wang; Zhihua Li; Ying Liu
Journal:  ACS Omega       Date:  2022-04-28

Review 2.  Drug Nanocrystals for Active Tumor-Targeted Drug Delivery.

Authors:  Linwei Lu; Qianzhu Xu; Jun Wang; Sunyi Wu; Zimiao Luo; Weiyue Lu
Journal:  Pharmaceutics       Date:  2022-04-06       Impact factor: 6.525

3.  Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris.

Authors:  Ivona Tomić; Sandra Miočić; Ivan Pepić; Dubravka Šimić; Jelena Filipović-Grčić
Journal:  Pharmaceutics       Date:  2021-04-16       Impact factor: 6.321

Review 4.  Naturally-Sourced Antibacterial Polymeric Nanomaterials with Special Reference to Modified Polymer Variants.

Authors:  Marian Rofeal; Fady Abdelmalek; Alexander Steinbüchel
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

5.  Bioresorbable hydrogels prepared by photo-initiated crosslinking of diacrylated PTMC-PEG-PTMC triblock copolymers as potential carrier of antitumor drugs.

Authors:  Yuandou Wang; Laishun Xi; Baogang Zhang; Qingzhen Zhu; Feng Su; Katarzyna Jelonek; Arkadiusz Orchel; Janusz Kasperczyk; Suming Li
Journal:  Saudi Pharm J       Date:  2020-01-31       Impact factor: 4.330

6.  Spironolactone-Loaded LeciPlexes as Potential Topical Delivery Systems for Female Acne: In Vitro Appraisal and Ex Vivo Skin Permeability Studies.

Authors:  Ayman Salama; Mohamed Badran; Mohammed Elmowafy; Ghareb M Soliman
Journal:  Pharmaceutics       Date:  2019-12-25       Impact factor: 6.321

7.  Preparation and Evaluation of Azelaic Acid Topical Microemulsion Formulation: In Vitro and In Vivo Study.

Authors:  Wan-Hsuan Hung; Ping-Kang Chen; Chih-Wun Fang; Ying-Chi Lin; Pao-Chu Wu
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.